DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Michael M. Goldberg, MD, MBA has been appointed to the Navidea Board of Directors.
Michael M. Goldberg has been a Managing Partner of Montaur Capital Partners since January 2007. Dr. Goldberg served as the Chief Executive Officer of Emisphere Technologies, Inc., from August 1990 to January 2007, Chairman of the Board of Directors from November 1991 to January 16, 2007 and President from August 1990 to October 1995. Prior to that, he served as Vice President of The First Boston Corp., where he was a founding member of the Healthcare Banking Group. He is or has been a Director of Alliqua, Inc., CorNova, Inc., Urigen Pharmaceuticals, Inc. and Adventrx Pharmaceuticals Inc. Dr. Goldberg received a B.S. from Rensselaer Polytechnic Institute, an MD from Albany Medical College of Union University in 1982 and an MBA from Columbia University Graduate School of Business in 1985.
“We are pleased to have Michael join the Board,” said Gordon Troup, Chairman of the Navidea Board of Directors. “Michael brings a wealth of knowledge of the financial and biopharmaceutical industries that make him an extremely valuable resource to our Board as we continue to execute on our growth plans.”
“I am excited to be joining the Board and have the opportunity to help deliver the greatest possible impact to patients and the medical community and return for investors with Navidea’s industry leading precision diagnostic products and technologies,” said Dr. Goldberg. “I look forward to working with the Board and Management to help Navidea realize the potential I believe Lymphoseek®, the Company’s pipeline, and Navidea’s business model have.”
About Navidea Biopharmaceuticals, Inc.
Navidea
Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company
focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is developing
multiple precision diagnostic products and platforms including NAV4694,
NAV5001, Manocept™ and RIGScan™,to help identify the sites and pathways
of undetected disease and enable better diagnostic accuracy, clinical
decision-making and, ultimately, patient care. Lymphoseek®
(technetium 99m tilmanocept) Injection, Navidea’s first
commercial product from the Manocept platform, was approved by the FDA
in March 2013. Navidea’s strategy is to deliver superior growth and
shareholder return by bringing to market novel radiopharmaceutical
agents and advancing the Company’s pipeline through selective
acquisitions, global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements within the meaning of the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
